ATE429505T1 - METHOD AND COMPOSITIONS FOR GENETIC PROTECTIVE AND THERAPEUTIC IMMUNIZATION - Google Patents

METHOD AND COMPOSITIONS FOR GENETIC PROTECTIVE AND THERAPEUTIC IMMUNIZATION

Info

Publication number: ATE429505T1
Authority: AT; Austria
Prior art keywords: genetic; compositions; protective; therapeutic immunization; immunization
Prior art date: 1996-02-21

Application number

AT97906764T

Other languages

German (de)

Inventor

Franco Lisziewicz Juliana Lori

Original Assignee

Genetic Immunity Kft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-02-21

Filing date

1997-02-20

Publication date

2009-05-15

1997-02-20 Application filed by Genetic Immunity Kft filed Critical Genetic Immunity Kft

2009-05-15 Application granted granted Critical

2009-05-15 Publication of ATE429505T1 publication Critical patent/ATE429505T1/en

Links

230000002068 genetic effect Effects 0.000 title 1
230000003053 immunization Effects 0.000 title 1
238000002649 immunization Methods 0.000 title 1
238000000034 method Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
230000001681 protective effect Effects 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/34—Antigenic peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
- C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Mycology (AREA)
Biophysics (AREA)
Oncology (AREA)
Hematology (AREA)
Plant Pathology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT97906764T 1996-02-21 1997-02-20 METHOD AND COMPOSITIONS FOR GENETIC PROTECTIVE AND THERAPEUTIC IMMUNIZATION ATE429505T1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US60462796A	1996-02-21	1996-02-21
PCT/US1997/002933 WO1997031119A1 (en)	1996-02-21	1997-02-20	Methods and compositions for protective and therapeutic genetic immunization

Publications (1)

Publication Number	Publication Date
ATE429505T1 true ATE429505T1 (en)	2009-05-15

Family

ID=24420371

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97906764T ATE429505T1 (en)	1996-02-21	1997-02-20	METHOD AND COMPOSITIONS FOR GENETIC PROTECTIVE AND THERAPEUTIC IMMUNIZATION

Country Status (12)

Country	Link
EP (1)	EP0882134B8 (en)
JP (1)	JP2000517290A (en)
AP (1)	AP964A (en)
AT (1)	ATE429505T1 (en)
AU (1)	AU726623B2 (en)
CA (1)	CA2246359A1 (en)
DE (1)	DE69739372D1 (en)
EA (2)	EA002020B1 (en)
ES (1)	ES2324745T3 (en)
NZ (1)	NZ331369A (en)
OA (1)	OA10842A (en)
WO (1)	WO1997031119A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3210997A (en) *	1996-05-24	1997-12-09	University Of Maryland At Baltimore	Dna vaccines for eliciting a mucosal immune response
US6797276B1 (en)	1996-11-14	2004-09-28	The United States Of America As Represented By The Secretary Of The Army	Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en)	1996-11-14	2006-01-05	Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc.	Transcutaneous immunization without heterologous adjuvant
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
NZ503334A (en) *	1997-09-15	2002-05-31	Genetic Immunity Llc	A gene delivering complex having a vector with a specific affinity for a foreign genetic material and a second site having a specific affinity for a receptor on an antigen presenting cell
JP2002508338A (en) *	1997-12-12	2002-03-19	ナルディニ，ルイジ	Therapeutic use of lentiviral vectors
WO1999047146A1 (en) *	1998-03-17	1999-09-23	Julianna Lisziwiewicz	Anti-hiv combination comprising hydroxyurea, ddi, and a protease inhibitor
US6461616B1 (en) *	2000-09-09	2002-10-08	Akzo Nobel Nv	EIAV p26 deletion vaccine and diagnostic
US20070025958A1 (en)	2000-10-27	2007-02-01	Hadden John W	Vaccine immunotherapy
CA2950109C (en)	2000-10-27	2019-02-19	John W. Hadden	Vaccine immunotherapy for immune suppressed patients
US7628980B2 (en)	2000-11-23	2009-12-08	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
US7097842B2 (en)	2000-11-23	2006-08-29	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en)	2000-11-23	2008-11-04	Bavarian Nordic A/S	Modified Vaccinia Ankara virus variant and cultivation method
HU230198B1 (en)	2000-11-23	2015-10-28	Bavarian Nordic A/S	Modified vaccinia ankara virus variant
EP1372708B1 (en)	2001-02-13	2008-06-18	GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY	Vaccine for transcutaneous immunization against travellers' diarrhoea
EP1456230A2 (en)	2001-12-04	2004-09-15	Bavarian Nordic A/S	Flavivirus ns1 subunit vaccine
EP1420822B2 (en)	2002-04-19	2017-07-05	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
AU2003264144C1 (en)	2002-09-05	2009-12-17	Bavarian Nordic A/S	Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
EP1590432A4 (en) *	2003-01-15	2008-05-14	Res Inst For Genetic And Human	Dna compositon and uses thereof
FR2872170B1 (en) *	2004-06-25	2006-11-10	Centre Nat Rech Scient Cnrse	NON-INTERACTIVE AND NON-REPLICATIVE LENTIVIRUS, PREPARATION AND USES
EP1797189A4 (en) *	2004-09-02	2010-05-19	Qun Chen	Encapsidation system for production of recombinant virus-like particles
GB0526211D0 (en) *	2005-12-22	2006-02-01	Oxford Biomedica Ltd	Viral vectors
US8765462B2 (en)	2007-05-04	2014-07-01	University Health Network	IL-12 immunotherapy for cancer
WO2009070639A1 (en)	2007-11-28	2009-06-04	Irx Therapeutics, Inc.	Method of increasing immunological effect
WO2010009465A2 (en) *	2008-07-18	2010-01-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Htlv-ii vector and methods of use
AU2010248761B2 (en)	2009-05-15	2016-02-11	Irx Therapeutics, Inc.	Vaccine immunotherapy
CN107050430B (en)	2009-12-08	2021-10-15	伊尔克斯治疗有限公司	Methods for reversing Langerhans cell immunosuppression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5342774A (en) *	1991-05-23	1994-08-30	Ludwig Institute For Cancer Research	Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
KR960701988A (en) *	1993-04-20	1996-03-28	윌리엄 에스. 로빈슨	METHODS AND MATERIALS FOR TREATMENT OF INDIVIDUALS INFECTED WITH INTRACELLULAR IN-FECTIOUS AGENTS
US6080408A (en) *	1994-08-22	2000-06-27	Connaught Laboratories Limited	Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles

1997
- 1997-02-20 AP APAP/P/1998/001320A patent/AP964A/en active
- 1997-02-20 EA EA199800746A patent/EA002020B1/en not_active IP Right Cessation
- 1997-02-20 EP EP97906764A patent/EP0882134B8/en not_active Expired - Lifetime
- 1997-02-20 AT AT97906764T patent/ATE429505T1/en not_active IP Right Cessation
- 1997-02-20 ES ES97906764T patent/ES2324745T3/en not_active Expired - Lifetime
- 1997-02-20 WO PCT/US1997/002933 patent/WO1997031119A1/en not_active Ceased
- 1997-02-20 DE DE69739372T patent/DE69739372D1/en not_active Expired - Lifetime
- 1997-02-20 JP JP09530399A patent/JP2000517290A/en not_active Ceased
- 1997-02-20 EA EA200100302A patent/EA003554B1/en not_active IP Right Cessation
- 1997-02-20 CA CA002246359A patent/CA2246359A1/en not_active Abandoned
- 1997-02-20 NZ NZ331369A patent/NZ331369A/en not_active IP Right Cessation
- 1997-02-20 AU AU21369/97A patent/AU726623B2/en not_active Ceased
1998
- 1998-08-18 OA OA9800147A patent/OA10842A/en unknown

Also Published As

Publication number	Publication date
NZ331369A (en)	2001-04-27
EP0882134B1 (en)	2009-04-22
EA002020B1 (en)	2001-12-24
EP0882134A1 (en)	1998-12-09
AP964A (en)	2001-05-11
EA200100302A1 (en)	2001-10-22
DE69739372D1 (en)	2009-06-04
AU726623B2 (en)	2000-11-16
OA10842A (en)	2001-08-14
AP9801320A0 (en)	1998-09-30
ES2324745T3 (en)	2009-08-13
CA2246359A1 (en)	1997-08-28
WO1997031119A1 (en)	1997-08-28
AU2136997A (en)	1997-09-10
EP0882134B8 (en)	2009-09-02
JP2000517290A (en)	2000-12-26
EA199800746A1 (en)	1999-02-25
EA003554B1 (en)	2003-06-26

Legal Events

Date	Code	Title	Description
2009-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69739372D1 (en)	2009-06-04	METHOD AND COMPOSITIONS FOR GENETICALLY PROTECTIVE AND THERAPEUTIC IMMUNIZATION
DE69519235D1 (en)	2000-11-30	HEMORRHOID COMPOSITIONS AND METHOD FOR USE THEREOF
DE69816789D1 (en)	2003-09-04	METHOD AND SYSTEM FOR GESTURE-CONTROLLED OPTION SELECTION
ATE351910T1 (en)	2007-02-15	COMPOSITIONS AND METHODS CONTAINING OB-FUSION PROTEIN
DE69526825D1 (en)	2002-07-04	Method and system for route selection
DE69534416D1 (en)	2005-10-06	METHOD AND FORMULATIONS FOR COMBATING DAMAGES
DE69814155D1 (en)	2003-06-05	SYSTEM AND METHOD FOR VIRTUAL INPUT
ATE397408T1 (en)	2008-06-15	METHOD FOR IMPROVED IMAGING AND PHOTODYNAMIC THERAPY
DE69839261D1 (en)	2008-04-30	METHOD AND COMPOSITIONS FOR TREATING INFLAMMABLE ENDURANCE DISEASES
DE69739887D1 (en)	2010-07-08	Method and device for block encryption
DE69717922D1 (en)	2003-01-30	CD-ROM player and method for controlling the same
DE69622421D1 (en)	2002-08-22	METHOD AND COMPOSITIONS FOR ADMINISTRATING MONOMERIC PROTEINS
DE69429867D1 (en)	2002-03-21	METHOD AND DEVICE FOR AUTHENTICATION
DE69422718D1 (en)	2000-02-24	GAS GENERATING BITETRAZOLEAMINE COMPOSITIONS AND METHOD FOR USE THEREOF
DE69534867D1 (en)	2006-05-11	Method and system for providing protected device drivers
DE59706789D1 (en)	2002-05-02	VOICE PROCESSING SYSTEM AND METHOD FOR VOICE PROCESSING
DE69635445T2 (en)	2006-06-14	ALKALIALUMINIUMHYDROXYCARBONATE COMPOSITION AND METHOD OF PREPARING THEREOF
DE69831519D1 (en)	2005-10-20	System and method for determining location
DE69721322D1 (en)	2003-05-28	COMPOSITION AND METHOD FOR INHIBITING POTATOES
EP0871771A4 (en)	2005-01-05	METHOD AND COMPOSITIONS FOR IMPLEMENTING THE HOMOLOGOUS RECOMBINATION
DE69717790D1 (en)	2003-01-23	METHOD FOR CDMA CODE GENERATION AND METHOD FOR CODE SELECTION
DE69720131D1 (en)	2003-04-30	Perspective transformation system and method
DE69822873D1 (en)	2004-05-06	COMPOSITIONS AND METHODS FOR WEIGHT REDUCTION
DE69423129D1 (en)	2000-04-06	System and method for displaying curves
DE69733137D1 (en)	2005-06-02	INHIBITORS OF PICORNAVIRUS 3C PROTEASE AND METHOD FOR THE PREPARATION AND USE THEREOF